Bavarian Nordic inks another major vaccine contract with Canada
As monkeypox cases continue to affect nations in North America and across the globe, Canada is looking to step up its prevention efforts via a boosted contract with Bavarian Nordic.
The Public Health Agency of Canada (PHAC) announced on Tuesday that it has changed its contract with the Danish drugmaker. The agreement will see Bavarian Nordic deliver its Jynneos vaccine, also known as Imvamune, to the PHAC at a value of $234 million, in addition to $180 million in contract options spanning 10 years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.